Cologne

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Toboroz

  NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

  NCT06890273· Forrás

• Toboroz

  NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

  NCT06494540· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Forrás

• Fut, nem toboroz

  Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

  NCT06380738· Forrás

• Toboroz

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· Forrás

• Fut, nem toboroz

  A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

  NCT05637112· Forrás

• Fut, nem toboroz

  Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer

  NCT04830709· Forrás

• Fut, nem toboroz

  Durvalumab and Tremelimumab for Pediatric Malignancies

  NCT03837899· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· 3. fázis· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Amiloidózis2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Elhízás1 toboroz
• Gyermekkori daganatok1 toboroz
• Hodgkin-limfóma1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhtestrák1 toboroz
• Mielóma multiplex1 toboroz
• Prosztatarák1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

  NCT04774380· 3. fázis· Forrás

• Lezárult

  Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

  NCT02499328· 1/2. fázis· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· Forrás

• Lezárult

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· 1/2. fázis· Forrás

• Lezárult

  Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

  NCT01078662· 2. fázis· Forrás